Head-to-head evidence
Pivekimab Sunirine vs SAR443579
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline
Pivekimab Sunirine
Marketed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT04086264 (registry estimate)
SAR443579
Developed by Sanofi
NCT05086315 · Phase 1/2 · terminated
This was an open-label, non-randomized, single-arm, first-in-human dose-escalation study of SAR443579 in relapsed or refractory acute leukemias and related blood cancers, with no control group. The primary goal was to find a safe dose by tracking dose-limiting toxicities, not to test efficacy, and the study was terminated before most of its planned expansion cohorts began.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pivekimab Sunirine's landscape · SAR443579's landscape